SUBSCRIBE
SUBSCRIBE
Grant Playter

Grant Playter

Freelance writer

Grant Playter is a professional freelance writer in the biopharma field, with a particular focus on investment and market trends. Connect with Grant on LinkedIn or reach out directly to grantplayter@gmail.com.

Illustration depicting a heart, a kidney, and GLP-1 agonist injection pens
GLP-1
Beyond Weight Loss: Novo and Lilly Look to Expand Their GLP-1 Pipelines
While type 2 diabetes and obesity are the primary conditions currently treated with blockbuster GLP-1 drugs, Novo Nordisk and Eli Lilly aim to enter additional markets.

July 22, 2024
 · 
4 min read
 · 
Grant Playter